Multiple Myeloma: Clinical Trials

3,676 trials for Multiple Myeloma, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

1690 completed, 517 recruiting, 485 terminated, 349 unknown. 1592 Phase 2, 1193 Phase 1, 382 Phase 3, 335 Not applicable, 88 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	1592	Completed 748, Terminated 247, Recruiting 182, Active not recruiting 144, Unknown 131, Withdrawn 85, Not yet recruiting 46, Suspended 6, Enrolling by invitation 3
Phase 1	1193	Completed 551, Terminated 211, Recruiting 147, Unknown 114, Active not recruiting 77, Withdrawn 45, Not yet recruiting 40, Suspended 8
Phase 3	382	Completed 197, Recruiting 51, Active not recruiting 48, Unknown 38, Terminated 28, Not yet recruiting 14, Withdrawn 5, Suspended 1
Not applicable	335	Completed 143, Recruiting 70, Terminated 41, Unknown 36, Not yet recruiting 21, Active not recruiting 14, Withdrawn 6, Suspended 3, Enrolling by invitation 1
Early Phase 1	88	Recruiting 30, Unknown 24, Not yet recruiting 12, Completed 8, Terminated 6, Active not recruiting 3, Withdrawn 3, Suspended 2
Phase 4	53	Completed 22, Recruiting 9, Unknown 8, Not yet recruiting 6, Active not recruiting 3, Withdrawn 3, Terminated 2

Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors	Not applicable	Not yet recruiting	University of Vermont Medical Center	33	2028-02-01	2026-08-25
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma Individual Exercise, Group Exercise - Multiple Myeloma	Not applicable	Suspended	Medical University of Vienna	45	2027-09-01	2026-10-09
Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma	Phase 1	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	10	2027-06-30	2026-08-27
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma	Phase 1	Withdrawn	Fred Hutchinson Cancer Center		2027-06-01	2026-09-11
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 2	Recruiting	National Cancer Institute (NCI)	80	2027-05-22	2026-10-28
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	74	2027-04-20	2026-10-26
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 1 / Phase 2	Recruiting	National Cancer Institute (NCI)	162	2027-04-12	2026-10-16
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)	Phase 2	Not yet recruiting	Zealand University Hospital	150	2027-03-01	2026-09-25
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM)	Phase 2	Not yet recruiting	University of Arkansas	50	2027-03-01	2026-09-02
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma	Phase 4	Not yet recruiting	Anne Louise Tølbøll Sørensen	400	2027-03-01	2026-03-16
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma	Phase 1	Not yet recruiting	University of Chicago	32	2027-02-23	2026-10-22
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma	Phase 3	Not yet recruiting	Kite, A Gilead Company	750	2027-02-01	2026-10-29
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization	Phase 2 / Phase 3	Not yet recruiting	The Affiliated People's Hospital of Ningbo University	70	2027-01-01	2026-09-30
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma	Phase 2 / Phase 3	Not yet recruiting	The Affiliated People's Hospital of Ningbo University	15	2027-01-01	2026-10-02
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma	Phase 3	Not yet recruiting	Kite, A Gilead Company	600	2027-01-01	2026-10-21
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	20	2026-12-31	2026-08-27
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	20	2026-12-31	2026-08-27
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM)	Phase 2 / Phase 3	Not yet recruiting	Alliance for Clinical Trials in Oncology	920	2026-12-23	2026-10-22
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible Ramantamig, Daratumumab, Bortezomib - Multiple Myeloma	Phase 3	Not yet recruiting	Janssen Research & Development, LLC	1000	2026-12-14	2026-10-29
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma	Phase 1 / Phase 2	Not yet recruiting	Universitätsklinikum Hamburg-Eppendorf	220	2026-12-01	2026-05-20

Multiple Myeloma: Clinical Trials

3,676 trials for Multiple Myeloma, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

By phase and status

Trials newest first · largest first

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Top investigators

Results publications

NIH funding